Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
复制标题
DOI：
10.3324/haematol.2019.234096
复制
发表时间：
2021-02-01
期刊：
影响因子：
10.1
通讯作者：
Morishita K
中科院分区：
文献类型：
--
作者：
Nakahata S;Syahrul C;Nakatake A;Sakamoto K;Yoshihama M;Nishikata I;Ukai Y;Matsuura T;Kameda T;Shide K;Kubuki Y;Hidaka T;Kitanaka A;Ito A;Takemoto S;Nakano N;Saito M;Iwanaga M;Sagara Y;Mochida K;Amano M;Maeda K;Sueoka E;Okayama A;Utsunomiya A;Shimoda K;Watanabe T;Morishita K
成人T细胞白血病/白血病（ATLL）是一种侵袭性外周T细胞恶性肿瘤，由人类T细胞白血病病毒1型（HTLV-1）感染引起。我们最近发现，细胞粘附分子1（CADM 1），免疫球蛋白超家族的成员，是特异性和一致性过表达的ATLL细胞，并作为一种新的细胞表面标志物的功能。在这项研究中，我们首先表明，可溶性形式的CADM 1（sCADM 1）分泌的ATLL细胞主要是选择性剪接。在开发了sCADM 1的α-联免疫吸附试验（AlphaLISA）后，我们发现血浆sCADM 1浓度在从惰性到侵袭性ATLL的疾病进展过程中逐渐增加。尽管其他已知的肿瘤负荷生物标志物如可溶性白细胞介素2受体α（sIL-2 R α）在ATLL进展期间也随sCADM 1增加，但生物标志物的多变量统计分析显示，仅血浆sCADM 1被选为侵袭性ATLL的特异性生物标志物，表明血浆sCADM 1可能是侵袭性ATLL的潜在危险因素。此外，血浆sCADM 1是监测化疗反应以及预测ATLL复发的有用标志物。此外，sCADM 1浓度在惰性型和侵袭型ATLL之间的变化比CD 4 + CADM 1 + ATLL细胞百分比的变化更显著。由于血清sIL-2 R α水平较高的HTLV-1相关性脊髓病/热带痉挛性轻瘫（HAM/TSP）患者的血浆sCADM 1值在正常范围内，因此sCADM 1的测量可能成为区分ATLL和其他炎性疾病（包括HAM/TSP）的有用工具。
Adult T-cell leukemia/leukemia (ATLL) is an aggressive peripheral T-cell malignancy, caused by infection with the human T-cell leukemia virus type 1 (HTLV-1). We recently showed that the cell adhesion molecule 1 (CADM1), a member of the immunoglobulin superfamily, is specifically and consistently overexpressed in ATLL cells, and functions as a novel cell surface marker. In this study, we first show that a soluble form of CADM1 (sCADM1) is secreted from ATLL cells by mainly alternative splicing. After developing the Alpha linked immunosorbent assay (AlphaLISA) for sCADM1, we show that plasma sCADM1 concentrations gradually increased during disease progression from indolent to aggressive ATLL. Although other known biomarkers of tumor burden such as soluble interleukin-2 receptor α (sIL-2Rα) also increased with sCADM1 during ATLL progression, multivariate statistical analysis of biomarkers revealed that only plasma sCADM1 was selected as a specific biomarker for aggressive ATLL, suggesting that plasma sCADM1 may be a potential risk factor for aggressive ATLL. In addition, plasma sCADM1 is a useful marker for monitoring response to chemotherapy as well as for predicting relapse of ATLL. Furthermore, the change in sCADM1 concentration between indolent and aggressive type ATLL was more prominent than the change in the percentage of CD4+CADM1+ ATLL cells. As plasma sCADM1 values fell within normal ranges in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with higher levels of serum sIL-2Rα, the measurement of sCADM1 may become a useful tool to discriminate between ATLL and other inflammatory diseases, including HAM/TSP.
登录
查看更多内容
影响因子：
6
作者：
Murray, Paul G.;Fan, Yichao;Tao, Qian
通讯作者：
Tao, Qian
影响因子：
5.4
作者：
Dewan, M. Zahidunnabi;Takamatsu, Naofumi;Morishita, Kazuhiro
通讯作者：
Morishita, Kazuhiro
影响因子：
6.7
作者：
Manivannan K;Rowan AG;Tanaka Y;Taylor GP;Bangham CR
通讯作者：
Bangham CR
DOI：
10.1073/pnas.0712202105
发表时间：
2008-05-20
影响因子：
11.1
作者：
Kurosawa, Gene;Akahori, Yasushi;Kurosawa, Yoshikazu
通讯作者：
Kurosawa, Yoshikazu
影响因子：
2.2
作者：
McGiven, John A.;Sawyer, Jason;Stack, Judy A.
通讯作者：
Stack, Judy A.